This study will help to better understand the persistence rate to antifibrotic (AF) treatment in real life in France and to identify potential areas for improvement by investigating the factors associated with a non-persistence rate to AF treatment. Primary objective of the study is to measure the percentage of patients still treated up to 30 months after AF treatment initiation.
Study Type
OBSERVATIONAL
Enrollment
10,646
Nintedanib
Pirfenidone
Clinityx
Boulogne-Billancourt, France
Persistence to antifibrotic (AF) treatment (measured as percentage of patients still treated up to 30 months after AF treatment initiation)
Time frame: up to 30 months
AF prevalence in French population
Time frame: up to 5 years
AF incidence in French population
Time frame: up to 4 years
Number of AF treated patients split by indication
Indications: * Idiopathic Pulmonary Fibrosis (IPF) * Interstitial Lung Disease associated with Systemic Sclerosis (SSc-ILD) * Progressive Pulmonary Fibrosis (PPF)
Time frame: up to 2 years
Number of patients adherent to AF treatment
In incident AF patients, percentage of days covered (PDC) will be calculated at different time point to measure the adherence to AF treatment for patients persistent to treatment at this time point. The PDC is the ratio dividing the number of days exposed by the number of days in the period evaluated. A PDC≥ 80% is considered as a good adherence to medication.
Time frame: up to 30 months
Percentage of the target cumulative dose of treatment received by the patients
Time frame: up to 30 months
Influence of factors (yes/no) associated with persistence to AF treatments
For a pre-determined list of variables (as defined in the study protocol) in incident AF patients, a multivariate time-dependant Cox model will test several covariates to check if they are associated with persistence to AF treatment.
Time frame: up to 30 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Number of patients with switch from one AF treatment to the another with no treatment stop
Time frame: up to 5 years
Number of patients at site of follow-up (identified as 2 lung function tests performed in the center)
Time frame: up to 5 years
Overall Survival (defined as time from index date (first reimbursement of AF treatment) to death from any cause)
Time frame: up to5 years
Event-free survival
Defined as the time from index date to * oxygenotherapy onset * hospitalisation for respiratory exacerbations * hospitalisation for other respiratory diseases * ath from any cause
Time frame: up to 5 years